Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
34
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Enlivex Ltd. market cap is $1.79M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Enlivex Ltd. 52 week high is $434.40 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Enlivex Ltd. 52 week low is $1.00 as of November 20, 2026.
Enlivex Ltd. stock price today is $1.05.
Enlivex Ltd. stock price yesterday was $1.17.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Enlivex Ltd. P/B ratio is 0.0003.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Enlivex Ltd. 50-day moving average is $5.14.